RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Another key factor increasing the odds of an eventual buyout is that Cortex's benzamide compounds are the only ones to have had success in human trials. Lilly's biarylpropylsulfonamides and Servier's benothiadiazides (both high impacts) looked good in animal models, but didn't have the required safety characteristics in humans. Cortex's new breakthrough high impacts like CX-1837 not only have a much wider therapeutic index than any previous high impacts, but the metabolic stability has been increased to provide a halflife of potentially over 20 hours in humans.

In addition, Cortex has the low impacts - an area all to itself. These compounds are ultrasafe, and CX-717's phenomenal ADHD Phase 2a results definitely attracted some BP/pharma attention, with Org-26576/Schering taking up where CX-717 left off.

Cortex clearly has the best AMPA upmodulation technology out there, and superior/unique platform technologies like this will be attractive acquisition targets.